News

Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A

STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) - including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay - today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M).

Read more

Bilan – Janvier 2020 : Innovation - featuring STALICLA CEO

Lynn Durham, fondatrice de la startup genevoise Stalicla, veut proposer un traitement personnalisé adapté à chaque patient.

Read more

STALICLA CEO & Founder, Lynn-Allison Durham will be speaking January 12th, 2020 on NeuroTech, software and diagnostics expert panel at SACHS Neuroscience Innovation Forum_Pre-JP Morgan, in San Francisco.

CEO & Founder,  will be speaking on expert panel on NeuroTech, software and diagnostics- at hashtagSACHS_NIF _Pre-JP Morgan in San Francisco. She will share STALICLA’s experience of developing a highly domain specific AI platform to accelerate precision medicine for patients with neurodevelopmental disorders

Read more

AGEFI - 27 Novembre 2019 : Stalicla accélère sa croissance vers le traitement de l’autisme

La biotech genevoise Stalicla annonce une levée de fonds de 8 millions de francs pour la mi-décembre. La société espère pouvoir démarrer les tests cliniques de son traitement durant la première moitié de 2020.

Read more

TRIBUNE DE GENEVE - 20 Novembre 2019 : Nouvelle étape dans la lutte contre l’autisme de Stalicla

L’équipe de Lynn Durham est en passe d’attirer 8millions de francs. Premier traitement testé l’an prochain.

Read more

Search for content on Stalicla...